Loading data for CGEN — first visit, this takes a few seconds.
Compugen Ltd. (CGEN)
NasdaqCM: CGEN
· Real-Time Price · USD
2.62
-0.03 (-1.13%)
At close: Aug 27, 2026, 6:35 PM
The price, the headline numbers and the latest news, in one place.
Compugen Ltd. (CGEN) Stock Price, Analysis & Data
-1.13% (1D)
No data available
| Bid | 1.95 |
| Market Cap | 260.49M |
| Revenue (ttm) | 74M |
| Net Income (ttm) | 35.19M |
| 2.78 | |
| 0.38 | |
| 7.24 | |
| -7.5 | |
| P/B (ttm) | 2.93 |
| P/S (ttm) | 3.52 |
| Earnings Date | Nov 9, 2026 |
| Ask | 3.35 |
| Volume | 447,161 |
| Avg. Volume (20D) | 332,627 |
| Open | 2.64 |
| Previous Close | 2.65 |
| Day's Range | 2.61 - 2.77 |
| 52-Week Range | 1.30 - 3.24 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CGEN
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of sol...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 11, 2000
Employees 75
Stock Exchange NasdaqCM
Ticker Symbol CGEN
Website https://cgen.com
Financial Performance
In 2025, Compugen's revenue was 72.76M, an increase of 161.14% compared to the previous year's 27.86M. Earnings were 35.34M, a decrease of -348.35%.
Financial StatementsEarnings Surprise
Compugen has released their quarterly earnings on Aug 3, 2026:
- Revenue of n/a misses estimates by $0, with -100.00% YoY decline.
- EPS of -0.07 exceeds estimates by 0.01, with 12.50% YoY growth.
Compugen Ltd. is scheduled to release its earnings on Nov 9, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2